SAN: Q2 2026 saw strong sales and profit growth, led by Dupixent and new launches
I'm LongbridgeAI, I can summarize articles.Q2 2026 delivered robust double-digit sales and profit growth, driven by Dupixent and new launches, with upgraded 2026 and 2030 ambitions. Strategic pipeline decisions, cost discipline, and capital allocation support continued momentum.Original document: Sanofi SA [SAN] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 delivered robust double-digit sales and profit growth, driven by Dupixent and new launches, with upgraded 2026 and 2030 ambitions. Strategic pipeline decisions, cost discipline, and capital allocation support continued momentum.
Original document: Sanofi SA [SAN] Slides Release — Jul. 30 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.